Evidence map›Paper›PMID 38445744›Full record

Trial reportJournal of the National Cancer Institute2024

Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial.

Roshan Paudel, Andrea C Enzinger, Hajime Uno, Christine Cronin, Sandra L Wong, Don S Dizon, Hannah Hazard Jenkins, Jessica Bian, Raymond U Osarogiagbon, Roxanne E Jensen and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyPragmatic Clinical Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03850912 (SIMPRO Research Center), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03850912 nacompletednot on this map

SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2019 to 2025Enrolled42,808ConditionsOther Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic CancerArmsStakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview, SASS Questionnaire, eSyM
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Roshan PaudelDana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8584-7045
Andrea C EnzingerDana-Farber Cancer Institute, Boston, MA, USA.
Hajime UnoDana-Farber Cancer Institute, Boston, MA, USA.
Christine CroninDana-Farber Cancer Institute, Boston, MA, USA.
Sandra L WongDartmouth Hitchcock Medical Center, Lebanon, NH, USA.ORCID 0000-0002-8594-6086
Don S DizonLifespan Cancer Institute and Brown University, Providence, RI, USA.
Hannah Hazard JenkinsWest Virginia University Cancer Center, Morgantown, WV, USA.
Jessica BianMaine Medical Center, Portland, ME, USA.
Raymond U OsarogiagbonBaptist Medical Center, Memphis, TN, USA.
Roxanne E JensenNational Cancer Institute, Rockville, MD, USA.
Sandra A MitchellNational Cancer Institute, Rockville, MD, USA.
Deborah SchragMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael J HassettDana-Farber Cancer Institute, Boston, MA, USA.
Dana-Farber Cancer Institute · USNational Cancer Institute · USBrown University · USDartmouth–Hitchcock Medical Center · USMaine Medical Center · USMemorial Sloan Kettering Cancer Center · USWest Virginia University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology PracticeUM1CA233080 · NCI · DANA-FARBER CANCER INST · PI HASSETT, MICHAEL JAMES, OSAROGIAGBON, RAYMOND U · 2018 to 2023
$9.1M
Baptist Health SystemDana-Farber Cancer InstituteDartmouth Hitchcock Medical CenterLifespan Health SystemNCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009172NCI NIH HHS UM1 CA233080NIH HHS UM1CA233080The IMPACT Consortium is a Cancer Moonshot Research InitiativeWest Virginia University
6 · The paper itself

Abstract

backgroundOptimal methods for deploying electronic patient-reported outcomes to manage symptoms in routine oncologic practice remain uncertain. The electronic symptom management (eSyM) program asks chemotherapy and surgery patients to self-report 12 common symptoms regularly. Feedback from nurses and patients led to changing the recall period from the past 7 days to the past 24 hours.

methodsUsing questionnaires submitted during the 16 weeks surrounding the recall period change, we assessed the likelihood of reporting severe or moderate and severe symptoms across 12 common symptoms and separately for the 5 most prevalent symptoms. Interrupted time-series analyses modeled the effects of the change using generalized linear mixed-effects models. Surgery and chemotherapy cohorts were analyzed separately. Study-wide effects were estimated using a meta-analysis method.

resultsIn total, 1692 patients from 6 institutions submitted 7823 eSyM assessments during the 16 weeks surrounding the recall period change. Shortening the recall period was associated with lower odds of severe symptom reporting in the surgery cohort (odds ratio = 0.65, 95% confidence interval = 0.46 to 0.93; P = .02) and lower odds of moderate and severe symptom reporting in the chemotherapy cohort (odds ratio = 0.83, 95% confidence interval = 0.71 to 0.97; P = .02). Among the most prevalent symptoms, 24-hour recall was associated with a lower rate of reporting postoperative constipation but no differences in reporting rates for other symptoms.

conclusionA shorter recall period was associated with a reduction in the proportion of patients reporting moderate-severe symptoms. The optimal recall period may vary depending on whether electronic patient-reported outcomes are collected for active symptom management, as a clinical trial endpoint, or another purpose. ClinicalTrials.gov ID NCT03850912.

Indexed as

NeoplasmsPatient Reported Outcome MeasuresAdultAgedConstipationFemaleHumansMaleMiddle AgedNauseaSelf ReportSeverity of Illness IndexSurveys and Questionnaires

Identifiers

PMID38445744
PMCPMC11223809
OpenAlexW4392517886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.